echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > CD28/ICOS dual T-cell co-stimulation inhibitor ALPN-101 for the prevention and treatment of acute transplant anti-host disease, while winning the FDA's designation of two orphan drugs

    CD28/ICOS dual T-cell co-stimulation inhibitor ALPN-101 for the prevention and treatment of acute transplant anti-host disease, while winning the FDA's designation of two orphan drugs

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Alpine Immune Sciences announced that the U.SFood and Drug Administration (FDA) has designated two orphan drugs for the use of its ALPN-101 (Selective Dual T-Cell Costimulation Factor Inhibitor) for the prevention and treatment of acute transplant anti-host disease (GVHD)ALPN-101 is a new Fc fusion protein for the induced T-cell co-stimulation ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to inhibit both CD28 and ICOSCD28 and ICOS are closely related co-stimulating molecules, which have partial overlapping function in T-cell activation and play an important role in a variety of autoimmune and inflammatory diseasesIn preclinical models of transplant resistance to host disease, inflammatory arthritis, connective tissue disease and multiple sclerosis, ALPN-101 was better than drugs that blocked the CD28-CD80/86 and ICOS-ICOSL pathways alonetransplant anti-host disease (GVHD) is the most common life-threatening complication of hematopoietic cell transplantationThis occurs when donor cells treat the receptor cells as heterogeneous and attack themAcute GVHD usually occurs in the first few weeks and months after transplantation and usually involves the skin, liver and gastrointestinal tractDrMitchell HGold, Executive Chairman and CEO of Alpine, said, "We are pleased to receive the FDA's designation of orphan medicine in the field of acute GVHD, as current standard therapies are not sufficient to prevent or control the diseaseThe unique mechanism of ALPN-101 has the potential to be used as a pioneering drug for patients with aggressive and destructive autoimmune/inflammatory disease, who today have little or no treatment options"
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.